ASCLETIS ANNOUNCES INITIATION OF PHASE I STUDY IN U.S. FOR ORAL AMYLIN RECEPTOR PEPTIDE AGONIST ASC36 FOR THE TREATMENT OF OBESITY

Reuters · 1d ago

Please log in to view news